BCM
ENGN icon

BML Capital Management’s enGene Therapeutics ENGN Stock Holding History

BML Capital Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$13.3M Hold
6,669,908
– – 7.11% 3
2026
Q2 		$11.5M Buy
+6,669,908
New +$27.2M 6.55% 3

Other funds holding ENGN

SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Peapod Lane Capital
Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return
Aldebaran Capital
Aldebaran Capital Carmel, Indiana $139M AUM 35.88% 1-Year Est. Return
F.L. Putnam Investment Management
F.L. Putnam Investment Management Lynnfield, Massachusetts $9.33B AUM 30.52% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
Quadrature Capital
Quadrature Capital London, United Kingdom $16.1B AUM 61.25% 1-Year Est. Return

BML Capital Management's ENGN Position: Q3 2026 in Review

BML Capital Management held its enGene Therapeutics (ENGN) position steady in Q3 2026 at 6,669,908 shares worth $13.3M. The position accounts for 7.11% of the portfolio, ranked #3.

BML Capital Management first reported a position in ENGN in Q2 2026 and has held it in 2 quarters since. 33 funds tracked by Wall St. Rank hold ENGN as of Q3 2026.

  • BML Capital Management held 6,669,908 shares of enGene Therapeutics worth $13.3M as of Q3 2026.
  • BML Capital Management left its enGene Therapeutics share count unchanged in Q3 2026.
  • enGene Therapeutics made up 7.11% of BML Capital Management's portfolio in Q3 2026, its #3 holding.
  • BML Capital Management first reported a position in enGene Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 33 funds tracked by Wall St. Rank held enGene Therapeutics as of Q3 2026.

Based on BML Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.